Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PhorMax Corp.

This article was originally published in Start Up

Executive Summary

PhorMax Corp. hopes to make filmless medical images affordable and widely accessible with CRView, its low-cost computed radiography system. CRView combines an imaging system and Web-based communications infrastructure to incorporate radiology images with other data in an electronic patient record, and facilitate its distribution within an institution or to interested parties on the outside. CRView will be priced at approximately $50,000, less than half the price of existing systems. And it is compatible with existing X-ray systems, which will allow imaging centers to become filmless without having to replace or reconfigure their existing equipment.

You may also be interested in...



Imaging and the Web

In the ten years or so since picture archiving and communications systems (PACS) were introduced, only 15% of hospitals in the US have implemented them in their radiology departments; the vast majority of hospitals handle most images as they have for years--on film and manually. The reasons are many, but cost is a big factor. Hospitals simply don't have money to pay for expensive PACS. A new business model, the application service provider (ASP) offers a solution. ASPs centralize alot of PACS services, serving multiple clients at once, and archiving digital images off-site at a central location. Hospitals pay on a per transaction basis and avoid the upfront costs of installing capital equipment. The web has made this possible because images can be transmitted over the Internet to off-site storage locations.

Long Hot Summer For Novel Drug Reviews Forecast At US FDA

Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.

Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza

The latest drug development news and highlights from our US FDA Performance Tracker.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

MT037101

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel